Boston Scientific Corp

• HCA reported strong third-quarter results exceeding Wall Street revenue and earnings expectations. • Management expects full-year operating performance in the upper half of guidance ranges. • Analysts reaffirmed favorable ratings and raised price targets following the earnings call.

• GE HealthCare reported Q3 results exceeding expectations and raised full-year guidance. • Total backlog reached record levels with significant revenue visibility and margin expansion. • Technical indicators show a MACD buy signal and an overbought RSI condition.

• Labcorp surpassed third-quarter Wall Street expectations on revenue and earnings. • Management raised its full-year financial outlook for revenue and earnings. • The company reported annual revenue of $13.95 billion.

• HCA reported third-quarter revenue of $19.85 billion and adjusted EPS of $7.22. • Uninsured patient volume created an estimated $400 million quarterly EBITDA headwind. • Third-quarter operating cash flow reached $4.46 billion, supporting capital allocation and repurchases.

• Boston Scientific lowered its full-year guidance due to weaker fourth-quarter projections. • A recent cybersecurity incident disrupted supply chains, manufacturing, and delayed order fulfillment. • International price erosion and intensifying market competition further pressured business segment profitability.

• Wall Street upgrades and UBS ratings changes drove Illumina stock upward. • Illumina will rejoin the S&P 500 index during rebalancing. • Annual revenue reached $4.34 billion with a net profit of $850 million.